false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Didactics
Immunotherapy in Gynecologic Malignancies
Immunotherapy in Gynecologic Malignancies
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The presentation focused on the role of immunotherapy, particularly checkpoint inhibition, in treating gynecologic malignancies. It highlighted the rising mortality rates in uterine and cervical cancers, stressing the need for innovative treatments beyond chemotherapy. Immunotherapy, well-studied in cancers like melanoma, shows promise in increasing survival rates. It has been approved for specific gynecologic cancers, with notable progress in endometrial and cervical cancers. Trials such as Keynote 158, 775, and A118 demonstrate improved responses when combining immunotherapy with standard treatments. Ongoing research aims to further optimize its efficacy across various cancer types.
Asset Subtitle
Olivia Lara
January 2025
Keywords
immunotherapy
gynecologic cancers
checkpoint inhibition
Keynote trials
innovative treatments
Contact
education@igcs.org
for assistance.
×